KRAS and Patent ductus arteriosus: Treatment via mesenchymal stem cell-derived exosomes with KRAS G12D siRNA is intended for patients with metastatic pancreatic cancer or PDA with KRAS G12D mutation, but Phase I trial for this treatment is not yet recruiting.